Advisors Preferred LLC Buys Shares of 141,405 Exelixis, Inc. (NASDAQ:EXEL)

Advisors Preferred LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 141,405 shares of the biotechnology company's stock, valued at approximately $3,384,000.

Other large investors also recently modified their holdings of the company. American Century Companies Inc. lifted its holdings in shares of Exelixis by 31.5% in the 3rd quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company's stock worth $30,811,000 after purchasing an additional 338,021 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Exelixis by 236.3% during the 4th quarter. State of Alaska Department of Revenue now owns 127,287 shares of the biotechnology company's stock valued at $3,053,000 after acquiring an additional 89,436 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Exelixis by 244.5% during the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company's stock valued at $2,839,000 after acquiring an additional 83,999 shares in the last quarter. Seven Eight Capital LP lifted its stake in Exelixis by 61.7% during the 3rd quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 8,305 shares in the last quarter. Finally, NewEdge Wealth LLC bought a new position in Exelixis during the 3rd quarter valued at $10,238,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on EXEL shares. Barclays raised their price objective on Exelixis from $24.00 to $25.00 and gave the company an "overweight" rating in a research note on Tuesday, January 30th. BTIG Research started coverage on Exelixis in a research note on Tuesday, December 19th. They set a "buy" rating and a $27.00 target price on the stock. William Blair reiterated an "outperform" rating on shares of Exelixis in a research note on Friday, January 26th. Stifel Nicolaus lifted their target price on Exelixis from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Friday, February 2nd. Finally, JMP Securities reiterated a "market outperform" rating and set a $27.00 target price on shares of Exelixis in a research note on Thursday, December 14th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $26.29.

Insider Activity

In other news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now owns 35,703 shares in the company, valued at approximately $857,229.03. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now owns 35,703 shares in the company, valued at approximately $857,229.03. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company's stock, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company's stock.

Exelixis Price Performance

EXEL stock traded down $0.35 during mid-day trading on Friday, reaching $23.14. 1,942,179 shares of the company traded hands, compared to its average volume of 2,343,687. The company has a market capitalization of $7.02 billion, a P/E ratio of 36.16, a P/E/G ratio of 0.62 and a beta of 0.54. Exelixis, Inc. has a 52-week low of $18.08 and a 52-week high of $24.34. The company has a fifty day moving average price of $22.16 and a 200-day moving average price of $22.05.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.02. The business had revenue of $479.65 million during the quarter, compared to analyst estimates of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. As a group, analysts forecast that Exelixis, Inc. will post 1.22 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.